Priser
Platform
Blog
Om os
Download
NXTG
Nextage Therapeutics
Tel Aviv Stock Exchange
0

Om

Nextage Therapeutics Ltd. is a biotechnology company focused on the development and commercialization of innovative therapeutics. Its primary function is to advance medical knowledge and treatment options through research and application in areas such as neuroscience and drug delivery systems. Nextage Therapeutics Ltd. plays a pivotal role in pioneering solutions that address complex medical challenges. The company's work is transformative, impacting pharmaceutical industries and healthcare sectors by introducing cutting-edge technologies and drug formulations. Through partnerships with research institutions and other biotech firms, Nextage Therapeutics Ltd. contributes significantly to the advancement of medical science, making strides in increasing treatment efficacy and patient outcomes worldwide. As a notable player within the biotechnology industry, it drives forward the possibilities of modern medicine, continually seeking to improve the quality of life for patients through its innovative approaches and strategic collaborations.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I NEXTAGE THERAPEUTICS MED ENDAVU: Køb Nextage Therapeutics ($NXTG) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Nextage Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

TickerNXTG
Land
Israel
Antal medarbejdere31
Hjemmesidenxtg.co.il
SektorSundhed
IndustriLægemiddelproducenter - Specialitet og generisk

Udbytter

0,27ILS
'03
Ex-udbytte-dato9. jun. 2003
Udbytteafkast0%